Artificial Blood Vessels companies

  • Report ID: 3743
  • Published Date: Jun 10, 2025
  • Report Format: PDF, PPT

Companies Dominating the Artificial Blood Vessels Landscape

    The current dynamics of the artificial blood vessels market are stimulated by fierce competency among key players, associated with ongoing technological advances and global expansion. Their strategic commercialization ensures maximum financial output from this merchandise. For instance, Humacyte and Medtronic concentrated their focus on producing bioengineered acellular vessels to consolidate the safety profiles and effectiveness of their pipelines. On the other hand, Terumo and BD magnify their efforts to develop and commercialize synthetic grafts to cope with the growing demand from minimally invasive applications.

    Top 20 of these innovators are:

    • B. Braun Melsungen AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Medtronic plc
    • Cook Medical Incorporated
    • Becton, Dickinson and Company (BD)
    • Humacyte Inc.
    • Jotec GmbH
    • LeMaitre Vascular Inc.
    • Techshot Inc.
    • W. L. Gore & Associates
    • Boston Scientific Corporation
    • Abbott Laboratories
    • MicroPort Scientific Corporation
    • Samsung Healthcare
    • United Surgical Industries
    • Malaysia Healthcare Innovations
    • Elekta AB
    • Getinge AB
    • Straub Medical AG

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the artificial blood vessels market was over USD 2.1 billion.

The market size for the artificial blood vessels market is projected to reach USD 4.6 billion by the end of 2037 expanding at a CAGR of 9% during the forecast period i.e., between 2025 and 2037.

The major players in the market are B. Braun Melsungen AG, Medtronic plc, Cook Medical Incorporated, Becton, Dickinson and Company (BD), Humacyte Inc., and others.

In terms of material type, the bioengineered segment is anticipated to garner the largest market share of 42.2% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 40.2% by the end of 2037 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos